Premium Only Content

Dr. David Wiseman's presentation at the C19 minisymposium session, November 7 2021
Re-analysis of policy-shaping studies on hydroxychloroquine and ivermectin reverses original findings to yield significant benefits. Review in the context of regulatory decisions on vaccines.
Abstract: It was with skepticism about the efficacy of hydroxychloroquine (HCQ) in Covid-19, that we read a paper reported in NEJM that was one of only two substantive papers cited by FDA in its revocation of the EUA for HCQ in June 2020. This was a study of postexposure prophylaxis (PEP) in persons experiencing a high or moderate risk exposure to Covid-19. Subjects enrolled in the study online and received HCQ or a folate placebo with the goal of preventing development of disease. Data presented in the supplemental appendix suggested, surprisingly, that the drug may have some efficacy in certain subpopulations. After contacting the PI, he pointed out a possible benefit of very early intervention. Exploring this observation, an examination of the raw dataset suggested that the intervention lag had likely been underestimated. After further data requests, we established that $52\%$ of subjects had received drug later than the overnight delivery assumed by the investigators. Correcting for this error yielded a $42\%$ reduction $(p=0.044)$ in Covid-19 compatible disease associated with HCQ given $\leq 3$ days from exposure. We found a similar problem in a companion study performed by the same team under the same logistical arrangements addressing early symptomatic subjects. We were unable to obtain corrected intervention lag data to determine if effects could be observed that were greater than the $20\%$ reduction of symptomatic Covid-19 reported originally. We also re-analyzed a study of early treatment using ivermectin (IVM) reported in JAMA in March 2021. The paper reported several execution errors or changes, notably the dosing of some placebo subjects with active drug, and the use of different types of placebos in different trial phases. Obtaining the raw dataset, accounting for these issues yielded a $56\%$ reduction $(p=0.033)$ of residual Covid-19. We will discuss these studies in the context of significant decisions made during the pandemic, particularly in light of recent decisions made by FDA and CDC regarding the Covid-19 vaccines.
Presented at the "Efficacy and safety statistics of COVID-19 treatment and prophylaxis protocols" minisymposium session at the 4th Annual Meeting of the SIAM Texas-Louisiana Section on November 7, 2021. This presentation does not necessarily represent the opinions or policies of SIAM, but it is protected under Academic Freedom in Research and the 1st Amendment of the United States Constitution.
-
1:51:29
Eleftherios Gkioulekas -- Research and Commentary
1 year agoCritical appraisal of multi-drug therapy in the ambulatory management of hypoxemic COVID-19 patients
117 -
1:22:51
Glenn Greenwald
7 hours agoThe Irony of John Bolton's Classified Docs Indictment; Prominent Dems Now Stutter When Asked About AIPAC; Celebs in Saudi Arabia Controversy: What Does it Reveal? | SYSTEM UPDATE #532
77.7K42 -
39:25
Donald Trump Jr.
6 hours agoFBI's Incredible Crime Crackdown, Plus my Message to ABC!! | TRIGGERED Ep.283
134K108 -
2:53:38
BigTallRedneck
4 hours agoPGA 2K25 - REDNECK'S WAY OR THE HIGHWAY
7.35K -
2:43:58
megimu32
3 hours agoON THE SUBJECT: MTV | From 24/7 Music to… Silence?
9135 -
4:38:09
Reolock
5 hours agoWoW Classic Hardcore | More Ultra? Maybe Mage?
3.28K -
1:02:05
BonginoReport
6 hours agoMusic Stars Go Viral For Anti-ICE Rants - Nightly Scroll w/ Hayley Caronia (Ep.157)
72.3K41 -
3:57:04
Amish Zaku
5 hours agoBaldur's Gate 3 - Four Player Co-op Act 3
1.81K -
LIVE
Barry Cunningham
4 hours agoKINDA BREAKING NEWS! JOHN BOLTON HAS BEEN INDICTED! WHO'S NEXT!
4,796 watching -
LIVE
a12cat34dog
3 hours agoTRIPPIN' INTO THE UNKNOWN :: The Evil Within 2 :: SPOOKTOBER CONTINUES {18+}
126 watching